Exact Sciences Corporation
EXAS US30063P1057
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -40% | -39% | 53% | -24% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Doyle James Edward |
42.02 USD |
1,485 Sold |
62,400 USD |
13/08/2025 | 13/08/2025 |
| Zanotti Katherine S |
53.20 USD |
3,207 Sold |
170,612 USD |
12/06/2025 | 13/06/2025 |
| Zanotti Katherine S |
53.20 USD |
3,207 Sold |
170,612 USD |
12/06/2025 | 13/06/2025 |
| Conroy Kevin T CEO |
51.35 USD |
19,500 Bought |
1,001,325 USD |
13/11/2024 | 13/11/2024 |
| Baranick Brian EX VP |
70.00 USD |
929 Sold |
65,030 USD |
08/10/2024 | 08/10/2024 |
| Baranick Brian EX VP |
70.00 USD |
929 Sold |
65,030 USD |
18/09/2024 | 18/09/2024 |
| Coward D Scott |
60.15 USD |
67 Sold |
4,030 USD |
30/04/2024 | 01/05/2024 |
| Elliott Jeffrey Thomas CFO |
60.15 USD |
136 Sold |
8,180 USD |
30/04/2024 | 01/05/2024 |
| Orville Jacob A MNGR |
60.15 USD |
102 Sold |
6,135 USD |
30/04/2024 | 01/05/2024 |
| Herriott James VP |
60.15 USD |
30 Sold |
1,805 USD |
30/04/2024 | 01/05/2024 |